Your browser doesn't support javascript.
loading
One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival.
Ito, Hiroki; Kondo, Keiichi; Kawahara, Takashi; Kaneta, Tomohiro; Tateishi, Ukihide; Ueno, Daiki; Namura, Kazuhiro; Kobayashi, Kazuki; Miyoshi, Yasuhide; Yumura, Yasushi; Makiyama, Kazuhide; Hayashi, Narihiko; Hasumi, Hisashi; Osaka, Kimito; Yokomizo, Yumiko; Teranishi, Jun-Ichi; Hattori, Yusuke; Inoue, Tomio; Uemura, Hiroji; Yao, Masahiro; Nakaigawa, Noboru.
Afiliação
  • Ito H; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kondo K; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kawahara T; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kaneta T; Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Tateishi U; Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Ueno D; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Namura K; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Kobayashi K; Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan.
  • Miyoshi Y; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Yumura Y; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Makiyama K; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Hayashi N; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Hasumi H; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Osaka K; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Yokomizo Y; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Teranishi JI; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Hattori Y; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Inoue T; Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Uemura H; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Yao M; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
  • Nakaigawa N; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. nakaigan@med.yokohama-cu.ac.jp.
Cancer Chemother Pharmacol ; 79(5): 855-861, 2017 May.
Article em En | MEDLINE | ID: mdl-28331985
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Everolimo / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Everolimo / Neoplasias Renais / Antineoplásicos Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Japão